2024
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3Lymphoma
2019
Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma
Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAmino Acid SubstitutionBiomarkers, TumorCentral Nervous System NeoplasmsCombined Modality TherapyGenetic Association StudiesGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLymphocytes, Tumor-InfiltratingMacrophagesMutationMyeloid Differentiation Factor 88Neoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorSignal TransductionSurvival AnalysisT-LymphocytesConceptsPD-1PD-L1Positive tumorsClinicopathologic correlatesT cellsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaPD-L1 positive tumorsEpstein-Barr virus infectionCentral nervous system lymphomaPotential targetable pathwayPD-L1 expressionProtein expressionNervous system lymphomaMyD88 protein expressionMYD88 L265P mutationSystemic lymphomaSystem lymphomaLymphoma patientsMacrophage infiltrationPoor prognosisVirus infectionTargetable pathwaysL265P mutationPathway alterations